Many people believe that urinary tract infections (UTIs) and incontinence are more common in women, but they can also affect ...

Patients receiving tolterodine ER plus tamsulosin experienced significant reductions in urgency urinary incontinence ... 12 weeks is beneficial for men with lower urinary tract symptoms, including ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Photo: Dr. Jennifer Kuo. Courtesy of Trinity Health Community News Dr. Jennifer Kuo, a urologist with Trinity Health IHA ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

[7] Among men with both DO and BOO that did not improve on alpha-blocker monotherapy, 73% did show symptomatic improvement after 3 months of tolterodine treatment. Urge urinary incontinence ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms ...

Additionally, the average daily number of urge urinary incontinence episodes was ... of Gemtesa is an important milestone for the men with unresolved symptoms of OAB while being treated for ...

The Urgent PC Modulation System first received FDA 510K marketing clearance (K052025) in 2005 for the treatment of urinary urgency, urinary frequency, and urge incontinence. The FDA considers the ...